SCHEMBL23608959

SCHEMBL23608959

Fc1ccc(CNc2cc(-c3ccccc3)c(NCCn3cncn3)cc2F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 1/20 0.42
CYP19A1 P11511 4/20 0.40
NAMPT P43490 1/20 0.39
TP53 P04637 2/20 0.38
TDO2 P48775 1/20 0.37
LMNA P02545 4/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPK1 P28482 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
QPCT Q16769 1/20 0.36
PDE11A Q9HCR9 1/20 0.36
FLT1 P17948 1/20 0.36
KDR P35968 1/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23608965 0.82 CYP19A1 (0.41) SMN1; SMN2HTTCYP19A1NAMPTTP53
SCHEMBL23608946 0.81 SMN1; SMN2 (0.41) SMN1; SMN2HTTCYP19A1NAMPTTP53
SCHEMBL23579428 0.81 NAMPT (0.40) SMN1; SMN2HTTCYP19A1NAMPTTDO2
SCHEMBL23609006 0.78 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP19A1NAMPTTP53
SCHEMBL23608999 0.78 CYP19A1 (0.43) SMN1; SMN2HTTCYP19A1TP53LMNA
SCHEMBL23608983 0.78 CYP19A1 (0.43) SMN1; SMN2HTTCYP19A1TP53LMNA
SCHEMBL23609046 0.76 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP19A1TP53LMNA
SCHEMBL23608984 0.76 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP19A1TP53LMNA
SCHEMBL23875558 0.75 TDO2 (0.47) SMN1; SMN2HTTCYP19A1NAMPTTP53
SCHEMBL29973640 0.73 CYP19A1 (0.40) SMN1; SMN2CYP19A1NAMPTLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117592-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-04-20 US disclosed
WO-2021133689-A2 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117592-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX5 SMN1; SMN2 243/4885HTT 549/4885CYP19A1 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.